Zobrazeno 1 - 10
of 1 181
pro vyhledávání: '"John V, Heymach"'
Autor:
Chenyang Li, Thinh T. Nguyen, Jian-Rong Li, Xingzhi Song, Junya Fujimoto, Latasha Little, Curtis Gumb, Chi-Wan B. Chow, Ignacio I. Wistuba, Andrew P. Futreal, Jianhua Zhang, Shawna M. Hubert, John V. Heymach, Jia Wu, Christopher I. Amos, Jianjun Zhang, Chao Cheng
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-14 (2024)
Abstract Lung Cancer remains the leading cause of cancer deaths in the USA and worldwide. Non-small cell lung cancer (NSCLC) harbors high transcriptomic intratumor heterogeneity (RNA-ITH) that limits the reproducibility of expression-based prognostic
Externí odkaz:
https://doaj.org/article/b6fe0a65261748579d8ae587987a1d01
Autor:
Lingzhi Hong, Sonia Patel, Leylah M. Drusbosky, Yuanyuan Xiong, Rongrong Chen, Ruixuan Geng, Simon Heeke, Monique Nilsson, Jia Wu, John V. Heymach, Yingyi Wang, Jianjun Zhang, Xiuning Le
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-11 (2024)
Abstract ERBB2 (HER2) represents a newly recognized actionable oncogenic driver in non-small cell lung cancer (NSCLC), with approved targeted therapy available. Understanding the landscape of ERBB2 alterations and co-occurring mutations is essential
Externí odkaz:
https://doaj.org/article/7d1f2cdad9384d7bb4c05d844e0f4351
Autor:
Mingchao Xie, Miljenka Vuko, Jaime Rodriguez-Canales, Johannes Zimmermann, Markus Schick, Cathy O’Brien, Luis Paz-Ares, Jonathan W. Goldman, Marina Chiara Garassino, Carl M. Gay, John V. Heymach, Haiyi Jiang, J. Carl Barrett, Ross A. Stewart, Zhongwu Lai, Lauren A. Byers, Charles M. Rudin, Yashaswi Shrestha
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-17 (2024)
Abstract Background We explored potential predictive biomarkers of immunotherapy response in patients with extensive-stage small-cell lung cancer (ES-SCLC) treated with durvalumab (D) + tremelimumab (T) + etoposide-platinum (EP), D + EP, or EP in the
Externí odkaz:
https://doaj.org/article/dac90161c2bf43f78841723ad0ac6b3b
Autor:
Biagio Ricciuti, MD, PhD, Arielle Elkrief, MD, Jessica Lin, MD, Jianjun Zhang, MD, Joao V. Alessi, MD, Giuseppe Lamberti, MD, PhD, Malini Gandhi, MD, Alessandro Di Federico, MD, Federica Pecci, MD, Xinan Wang, PhD, Maisam Makarem, MD, PhD, Cassio Murilo Hidalgo Filho, MD, Teresa Gorria, MD, Arushi Saini, BS, Cindy Pabon, MD, James Lindsay, PhD, Kathleen L. Pfaff, PhD, Emma L. Welsh, BS, Mizuki Nishino, MD, Lynette M. Sholl, MD, Scott Rodig, MD, Saadettin Kilickap, MD, Petra Rietschel, MD, Debra AG. McIntyre, PhD, Jean-Francois Pouliot, MD, Mehmet Altan, MD, Justin F. Gainor, MD, John V. Heymach, MD, Adam J. Schoenfeld, MD, Mark M. Awad, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 9, Pp 100675- (2024)
Introduction: Responses to first-line programmed cell death protein 1 inhibition vary among patients with metastatic NSCLC and a programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) greater than or equal to 50%. We previously reported impro
Externí odkaz:
https://doaj.org/article/b469726a5a6d43d08be740aa9e8f7bc9
Autor:
Sehhoon Park, Tae Hee Hong, Soohyun Hwang, Simon Heeke, Carl M. Gay, Jiyeon Kim, Hyun-Ae Jung, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Jong Ho Cho, Yong Soo Choi, Jhingook Kim, Young Mog Shim, Hong Kwan Kim, Lauren Averett Byers, John V. Heymach, Yoon-La Choi, Se-Hoon Lee, Keunchil Park
Publikováno v:
EBioMedicine, Vol 102, Iss , Pp 105062- (2024)
Summary: Background: Recent studies have reported the predictive and prognostic value of novel transcriptional factor-based molecular subtypes in small-cell lung cancer (SCLC). We conducted an in-depth analysis pairing multi-omics data with immunohis
Externí odkaz:
https://doaj.org/article/40a1e82c84034502bbbe4835972d5109
Autor:
Hui Li, Xin Hu, Matthew S. Ning, Gregory N. Fuller, John M. Stewart, Jared C. Gilliam, Jia Wu, Xiuning Le, Ara A. Vaporciyan, J. Jack Lee, Don L. Gibbons, John V. Heymach, Andrew Futreal, Jianjun Zhang
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Accurate diagnoses are crucial in determining the most effective treatment across different cancers. In challenging cases, morphology-based traditional pathology methods have important limitations, while molecular profiling can provide valuable infor
Externí odkaz:
https://doaj.org/article/fb21075e7e8349959fa6c94a843dfb1d
Autor:
Bingnan Zhang, MD, MBA, Whitney Lewis, PharmD, C. Allison Stewart, PhD, Benjamin B. Morris, PhD, Luisa M. Solis, MD, Alejandra Serrano, MD, Yuanxin Xi, PhD, Qi Wang, PhD, Elyse R. Lopez, MD, Kyle Concannon, MD, Simon Heeke, PhD, Ximing Tang, MD, PhD, Gabriela Raso, MD, Robert J. Cardnell, PhD, Natalie Vokes, MD, George Blumenschein, MD, Yasir Elamin, MD, Frank Fosella, MD, Anne Tsao, MD, Ferdinandos Skoulidis, MD, PhD, Celyne Bueno Hume, MD, Koji Sasak, MD, PhD, Jeff Lewis, BS, Waree Rinsurongkawong, PhD, Vadeerat Rinsurongkawong, PhD, Jack Lee, PhD, Hai Tran, PhD, Jianjun Zhang, MD, PhD, Don Gibbons, MD, PhD, Ara Vaporciyan, MD, Jing Wang, PhD, Keunchil Park, MD, PhD, John V. Heymach, MD, PhD, Lauren A. Byers, MD, Carl M. Gay, MD, PhD, Xiuning Le, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 2, Pp 100623- (2024)
Introduction: NSCLC transformation to SCLC has been best characterized with EGFR-mutant NSCLC, with emerging case reports seen in ALK, RET, and KRAS-altered NSCLC. Previous reports revealed transformed SCLC from EGFR-mutant NSCLC portends very poor p
Externí odkaz:
https://doaj.org/article/ff328939b00e48428ec63183f24ee037
Autor:
Loretta A. Williams, Meagan S. Whisenant, Tito R. Mendoza, Angela E. Peek, Donna Malveaux, Donna K. Griffin, Darcy A. Ponce, Bruno Palma Granwehr, Ajay Sheshadri, Katherine A. Hutcheson, Sara M. Ali, Susan K. Peterson, John V. Heymach, Charles S. Cleeland, Ishwaria M. Subbiah
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 7, Iss 1, Pp 1-11 (2023)
Abstract Background Symptom expression in SARS-CoV-2 infection (COVID-19) may affect patients already symptomatic with cancer. Patient-reported outcomes (PROs) can describe symptom burden during the acute and postacute stages of COVID-19 and support
Externí odkaz:
https://doaj.org/article/5ee4f7c411b045f7beeb11d09176a2f0
Autor:
Mehmet Altan, Quan-Zhen Li, Qi Wang, Natalie I. Vokes, Ajay Sheshadri, Jianjun Gao, Chengsong Zhu, Hai T. Tran, Saumil Gandhi, Mara B. Antonoff, Stephen Swisher, Jing Wang, Lauren A. Byers, Noha Abdel-Wahab, Maria C. Franco-Vega, Yinghong Wang, J. Jack Lee, Jianjun Zhang, John V. Heymach
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
The roles of preexisting auto-reactive antibodies in immune-related adverse events (irAEs) associated with immune checkpoint inhibitor therapy are not well defined. Here, we analyzed plasma samples longitudinally collected at predefined time points a
Externí odkaz:
https://doaj.org/article/44aa74a2e8c94542b05cdd6dd9c9df49
Autor:
Rakesh Kumar, Keunchil Park, Frances A Shepherd, John V Heymach, Quincy Chu, Sylvia Hartl, J Carl Barrett, Sonia Iyer, Parneet Cheema, Marianna Koczywas, Maximilian Hochmair, Giuseppe Galletti, Mark Gustavson, Brent Evans, Jan Cosaert
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/fc6c2d7f62824e51983bea009bbe51ac